Cargando…

Putative Transcriptomic Biomarkers in the Inflammatory Cytokine Pathway Differentiate Major Depressive Disorder Patients from Control Subjects and Bipolar Disorder Patients

Mood disorders consist of two etiologically related, but distinctly treated illnesses, major depressive disorder (MDD) and bipolar disorder (BPD). These disorders share similarities in their clinical presentation, and thus show high rates of misdiagnosis. Recent research has revealed significant tra...

Descripción completa

Detalles Bibliográficos
Autores principales: Powell, Timothy R., McGuffin, Peter, D'Souza, Ursula M., Cohen-Woods, Sarah, Hosang, Georgina M., Martin, Charlotte, Matthews, Keith, Day, Richard K., Farmer, Anne E., Tansey, Katherine E., Schalkwyk, Leonard C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3949789/
https://www.ncbi.nlm.nih.gov/pubmed/24618828
http://dx.doi.org/10.1371/journal.pone.0091076
_version_ 1782306937031884800
author Powell, Timothy R.
McGuffin, Peter
D'Souza, Ursula M.
Cohen-Woods, Sarah
Hosang, Georgina M.
Martin, Charlotte
Matthews, Keith
Day, Richard K.
Farmer, Anne E.
Tansey, Katherine E.
Schalkwyk, Leonard C.
author_facet Powell, Timothy R.
McGuffin, Peter
D'Souza, Ursula M.
Cohen-Woods, Sarah
Hosang, Georgina M.
Martin, Charlotte
Matthews, Keith
Day, Richard K.
Farmer, Anne E.
Tansey, Katherine E.
Schalkwyk, Leonard C.
author_sort Powell, Timothy R.
collection PubMed
description Mood disorders consist of two etiologically related, but distinctly treated illnesses, major depressive disorder (MDD) and bipolar disorder (BPD). These disorders share similarities in their clinical presentation, and thus show high rates of misdiagnosis. Recent research has revealed significant transcriptional differences within the inflammatory cytokine pathway between MDD patients and controls, and between BPD patients and controls, suggesting this pathway may possess important biomarker properties. This exploratory study attempts to identify disorder-specific transcriptional biomarkers within the inflammatory cytokine pathway, which can distinguish between control subjects, MDD patients and BPD patients. This is achieved using RNA extracted from subject blood and applying synthesized complementary DNA to quantitative PCR arrays containing primers for 87 inflammation-related genes. Initially, we use ANOVA to test for transcriptional differences in a ‘discovery cohort’ (total n = 90) and then we use t-tests to assess the reliability of any identified transcriptional differences in a ‘validation cohort’ (total n = 35). The two most robust and reliable biomarkers identified across both the discovery and validation cohort were Chemokine (C-C motif) ligand 24 (CCL24) which was consistently transcribed higher amongst MDD patients relative to controls and BPD patients, and C-C chemokine receptor type 6 (CCR6) which was consistently more lowly transcribed amongst MDD patients relative to controls. Results detailed here provide preliminary evidence that transcriptional measures within inflammation-related genes might be useful in aiding clinical diagnostic decision-making processes. Future research should aim to replicate findings detailed in this exploratory study in a larger medication-free sample and examine whether identified biomarkers could be used prospectively to aid clinical diagnosis.
format Online
Article
Text
id pubmed-3949789
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-39497892014-03-12 Putative Transcriptomic Biomarkers in the Inflammatory Cytokine Pathway Differentiate Major Depressive Disorder Patients from Control Subjects and Bipolar Disorder Patients Powell, Timothy R. McGuffin, Peter D'Souza, Ursula M. Cohen-Woods, Sarah Hosang, Georgina M. Martin, Charlotte Matthews, Keith Day, Richard K. Farmer, Anne E. Tansey, Katherine E. Schalkwyk, Leonard C. PLoS One Research Article Mood disorders consist of two etiologically related, but distinctly treated illnesses, major depressive disorder (MDD) and bipolar disorder (BPD). These disorders share similarities in their clinical presentation, and thus show high rates of misdiagnosis. Recent research has revealed significant transcriptional differences within the inflammatory cytokine pathway between MDD patients and controls, and between BPD patients and controls, suggesting this pathway may possess important biomarker properties. This exploratory study attempts to identify disorder-specific transcriptional biomarkers within the inflammatory cytokine pathway, which can distinguish between control subjects, MDD patients and BPD patients. This is achieved using RNA extracted from subject blood and applying synthesized complementary DNA to quantitative PCR arrays containing primers for 87 inflammation-related genes. Initially, we use ANOVA to test for transcriptional differences in a ‘discovery cohort’ (total n = 90) and then we use t-tests to assess the reliability of any identified transcriptional differences in a ‘validation cohort’ (total n = 35). The two most robust and reliable biomarkers identified across both the discovery and validation cohort were Chemokine (C-C motif) ligand 24 (CCL24) which was consistently transcribed higher amongst MDD patients relative to controls and BPD patients, and C-C chemokine receptor type 6 (CCR6) which was consistently more lowly transcribed amongst MDD patients relative to controls. Results detailed here provide preliminary evidence that transcriptional measures within inflammation-related genes might be useful in aiding clinical diagnostic decision-making processes. Future research should aim to replicate findings detailed in this exploratory study in a larger medication-free sample and examine whether identified biomarkers could be used prospectively to aid clinical diagnosis. Public Library of Science 2014-03-11 /pmc/articles/PMC3949789/ /pubmed/24618828 http://dx.doi.org/10.1371/journal.pone.0091076 Text en © 2014 Powell et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Powell, Timothy R.
McGuffin, Peter
D'Souza, Ursula M.
Cohen-Woods, Sarah
Hosang, Georgina M.
Martin, Charlotte
Matthews, Keith
Day, Richard K.
Farmer, Anne E.
Tansey, Katherine E.
Schalkwyk, Leonard C.
Putative Transcriptomic Biomarkers in the Inflammatory Cytokine Pathway Differentiate Major Depressive Disorder Patients from Control Subjects and Bipolar Disorder Patients
title Putative Transcriptomic Biomarkers in the Inflammatory Cytokine Pathway Differentiate Major Depressive Disorder Patients from Control Subjects and Bipolar Disorder Patients
title_full Putative Transcriptomic Biomarkers in the Inflammatory Cytokine Pathway Differentiate Major Depressive Disorder Patients from Control Subjects and Bipolar Disorder Patients
title_fullStr Putative Transcriptomic Biomarkers in the Inflammatory Cytokine Pathway Differentiate Major Depressive Disorder Patients from Control Subjects and Bipolar Disorder Patients
title_full_unstemmed Putative Transcriptomic Biomarkers in the Inflammatory Cytokine Pathway Differentiate Major Depressive Disorder Patients from Control Subjects and Bipolar Disorder Patients
title_short Putative Transcriptomic Biomarkers in the Inflammatory Cytokine Pathway Differentiate Major Depressive Disorder Patients from Control Subjects and Bipolar Disorder Patients
title_sort putative transcriptomic biomarkers in the inflammatory cytokine pathway differentiate major depressive disorder patients from control subjects and bipolar disorder patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3949789/
https://www.ncbi.nlm.nih.gov/pubmed/24618828
http://dx.doi.org/10.1371/journal.pone.0091076
work_keys_str_mv AT powelltimothyr putativetranscriptomicbiomarkersintheinflammatorycytokinepathwaydifferentiatemajordepressivedisorderpatientsfromcontrolsubjectsandbipolardisorderpatients
AT mcguffinpeter putativetranscriptomicbiomarkersintheinflammatorycytokinepathwaydifferentiatemajordepressivedisorderpatientsfromcontrolsubjectsandbipolardisorderpatients
AT dsouzaursulam putativetranscriptomicbiomarkersintheinflammatorycytokinepathwaydifferentiatemajordepressivedisorderpatientsfromcontrolsubjectsandbipolardisorderpatients
AT cohenwoodssarah putativetranscriptomicbiomarkersintheinflammatorycytokinepathwaydifferentiatemajordepressivedisorderpatientsfromcontrolsubjectsandbipolardisorderpatients
AT hosanggeorginam putativetranscriptomicbiomarkersintheinflammatorycytokinepathwaydifferentiatemajordepressivedisorderpatientsfromcontrolsubjectsandbipolardisorderpatients
AT martincharlotte putativetranscriptomicbiomarkersintheinflammatorycytokinepathwaydifferentiatemajordepressivedisorderpatientsfromcontrolsubjectsandbipolardisorderpatients
AT matthewskeith putativetranscriptomicbiomarkersintheinflammatorycytokinepathwaydifferentiatemajordepressivedisorderpatientsfromcontrolsubjectsandbipolardisorderpatients
AT dayrichardk putativetranscriptomicbiomarkersintheinflammatorycytokinepathwaydifferentiatemajordepressivedisorderpatientsfromcontrolsubjectsandbipolardisorderpatients
AT farmerannee putativetranscriptomicbiomarkersintheinflammatorycytokinepathwaydifferentiatemajordepressivedisorderpatientsfromcontrolsubjectsandbipolardisorderpatients
AT tanseykatherinee putativetranscriptomicbiomarkersintheinflammatorycytokinepathwaydifferentiatemajordepressivedisorderpatientsfromcontrolsubjectsandbipolardisorderpatients
AT schalkwykleonardc putativetranscriptomicbiomarkersintheinflammatorycytokinepathwaydifferentiatemajordepressivedisorderpatientsfromcontrolsubjectsandbipolardisorderpatients